Clinical Trials Logo
  1. Home
  2. Eczema
  3. NCT04378569

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema Clinical Trial

Official title:
A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema

Clinical Trial Summary

This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Clinical Trial Description

This is a Phase 1/2b multiple dose, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04378569
Study type Interventional
Source Arcutis Biotherapeutics, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 20, 2020
Completion date February 24, 2021
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05545215 - Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema
Completed NCT05486117 - Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema Phase 1
Recruiting NCT06004050 - A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05682859 - Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) Phase 4
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT03683719 - Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema Phase 2
Completed NCT04872101 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) Phase 3
Completed NCT01482663 - Chronic Hand Eczema - Self-management and Prognosis N/A
Completed NCT04871711 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05026554 - Characterization of Chronic Hand Eczema
Completed NCT05259722 - A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema Phase 3
Recruiting NCT03861455 - Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids Phase 2
Recruiting NCT05355818 - Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema Phase 3
Completed NCT04949841 - Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials Phase 3
Completed NCT03246776 - Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan Phase 4
Not yet recruiting NCT06283550 - Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Phase 2